Sentences with phrase «cancer research center study»

A Fred Hutchinson Cancer Research Center study of community - based exercise for cancer survivors that focused on strength training found such activity is both safe and effective in terms of physical and psychosocial benefit.

Not exact matches

In 2010, researchers from the University of Michigan Comprehensive Cancer Center published a study in the journal Clinical Cancer Research showing that sulforaphane had the ability to kill breast cancer stem cells in mice and in lab cultures, and it also prevented the growth of new tumor Cancer Center published a study in the journal Clinical Cancer Research showing that sulforaphane had the ability to kill breast cancer stem cells in mice and in lab cultures, and it also prevented the growth of new tumor Cancer Research showing that sulforaphane had the ability to kill breast cancer stem cells in mice and in lab cultures, and it also prevented the growth of new tumor cancer stem cells in mice and in lab cultures, and it also prevented the growth of new tumor cells.

Pete has supported legislation to increase Medicare reimbursements for screening and diagnostic mammographies; fund research centers to study the relationship between the environment and breast cancer; and require insurance companies to guarantee at least 48 hours hospital care after a mastectomy.»

At 10 a.m., LG Kathy Hochul delivers remarks at a Roswell Park Cancer Institute announcement, Research Studies Center, Gaylord / Cary Meeting Rooms, Elm & Carlton streets, Buffalo.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

He completed his neurology residency at Walter Reed Army Medical Center, conducted further studies under a neuropharmacology research fellowship at Sloan - Kettering Cancer Center, and completed a neurointensive care fellowship at Johns Hopkins Hospital.

«This research represents a big step forward in understanding why some tumors are more aggressive than others and being able to predict rationally which neoantigens will be the most effective at stimulating an immune response,» said Dr. Balachandran, a member of the David M. Rubenstein Center for Pancreatic Cancer Research at MSK, and corresponding author of the companion study inresearch represents a big step forward in understanding why some tumors are more aggressive than others and being able to predict rationally which neoantigens will be the most effective at stimulating an immune response,» said Dr. Balachandran, a member of the David M. Rubenstein Center for Pancreatic Cancer Research at MSK, and corresponding author of the companion study inResearch at MSK, and corresponding author of the companion study in Nature.

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

A Yale Cancer Center research team conducted a study to determine how those tumor cells manage to grow outside the lungs.

An experimental drug in early development for aggressive brain tumors can cross the blood - brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibcancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors.

«Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV - related vulvar and vaginal cancer, 70 to 85 percent of high - grade cervical disease in females, and approximately 90 percent of HPV - related anal cancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Mocancer, 90 percent of HPV - related vulvar and vaginal cancer, 70 to 85 percent of high - grade cervical disease in females, and approximately 90 percent of HPV - related anal cancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Mocancer, 70 to 85 percent of high - grade cervical disease in females, and approximately 90 percent of HPV - related anal cancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Mocancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at MoCancer at Moffitt.

However, in the largest study of its kind so far, scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now shown that the risk of death from heart disease in breast cancer patients following radiotherapy or chemotherapy is no higher than it is among the average populCancer Research Center (DKFZ) in Heidelberg have now shown that the risk of death from heart disease in breast cancer patients following radiotherapy or chemotherapy is no higher than it is among the average populcancer patients following radiotherapy or chemotherapy is no higher than it is among the average population.

The first author of the Science paper is Laura Gaydos, a graduate student in Strome's lab at UC Santa Cruz who led the study for her Ph.D. thesis and is now a postdoctoral researcher at Fred Hutchinson Cancer Research Center in Seattle.

«This approach offers a potentially new and safe way of treating liver cancer, and possibly other cancers,» said study senior author Dr. Ian Corbin, Assistant Professor in the Advanced Imaging Research Center (AIRC) and of Internal Medicine at UT Southwestern.

«It may be the treatments used for migraines that are responsible for this risk reduction rather than the migraine itself,» says study co-author Christopher Li, a cancer epidemiologist at Fred Hutchinson Cancer Research Center in Secancer epidemiologist at Fred Hutchinson Cancer Research Center in SeCancer Research Center in Seattle.

Center for Nuclear Receptors & Cell Signaling (CNRCS) Assistant Professor Daniel Frigo and his research team recently published a study investigating the processes through which androgen receptors affect prostate cancer progression.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

A study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified an abnormal metabolic pathway that drives cancer - cell growth in a particular glioblastoma suCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified an abnormal metabolic pathway that drives cancer - cell growth in a particular glioblastoma suCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified an abnormal metabolic pathway that drives cancer - cell growth in a particular glioblastoma sucancer - cell growth in a particular glioblastoma subtype.

Dr. David Fredricks, a physician - scientist at Fred Hutchinson Cancer Research Center and senior author of the study, said the results could lead to a better understanding of how biological conditions may promote infection by the virus that causes AIDS, and perhaps offer targets for future prevention rResearch Center and senior author of the study, said the results could lead to a better understanding of how biological conditions may promote infection by the virus that causes AIDS, and perhaps offer targets for future prevention researchresearch.

Study co-leader Wyndham Wilson, M.D., Ph.D., NCI Center for Cancer Research, added, «This is the first clinical study to demonstrate the importance of precision medicine in lymphomas.&rStudy co-leader Wyndham Wilson, M.D., Ph.D., NCI Center for Cancer Research, added, «This is the first clinical study to demonstrate the importance of precision medicine in lymphomas.&rstudy to demonstrate the importance of precision medicine in lymphomas.»

«The findings of both studies support a growing body of research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stcancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stCancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stCancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both studies.

A new study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) reveals details about how such viral DNA insertion complexes hunt for a suitable spot and how quickly insertion happens at the chosen site.

A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — Jcancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — JCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — JCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

Jean - Pierre Issa, MD, Director of the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine and co-Leader of the Cancer Epigenetics Program at the Fox Chase Cancer Center is lead author of the study, which has been published August 19 in the journal, Lancet Oncology.

This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.

Now, a new study led by infectious disease researcher Dr. Sachiko Seo, formerly of Fred Hutch and now a physician at the National Cancer Research Center East in Chiba, Japan, and Boeckh and published last month in the journal Haematologica has found that like more «serious» viruses, rhinovirus can cause pneumonia — and when it does, it can be deadly to those recovering from transplantation.

In the most comprehensive study ever on the impact of smoking on cardiovascular disease in older people, epidemiologist Dr. Ute Mons from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) analyzed 25 individual studies, compiling data from over half a million individuals age 60 and older.

The preclinical study was led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

Jeroen Roelofs, assistant professor in the Division of Biology and a research affiliate with the university's Johnson Cancer Research Center, led a study on a specific step in the assembly of protresearch affiliate with the university's Johnson Cancer Research Center, led a study on a specific step in the assembly of protResearch Center, led a study on a specific step in the assembly of proteasomes.

«This really is the most lethal form of prostate cancer,» says Michael Schweizer, M.D., researcher at Fred Hutchinson Cancer Research Center and contributor to the study during his recent fellowship at Johns Hocancer,» says Michael Schweizer, M.D., researcher at Fred Hutchinson Cancer Research Center and contributor to the study during his recent fellowship at Johns HoCancer Research Center and contributor to the study during his recent fellowship at Johns Hopkins.

«Other studies have looked at racial disparities in treatment and still others have focused on racial differences in survival rates of cancer patients, but our research attempted to go further by demonstrating the impact of race - based inequalities in cancer treatment on survival rates of black colorectal cancer patients,» said James D. Murphy, MD, MS, assistant professor and chief of the Radiation Oncology Gastrointestinal Tumor Service at UC San Diego Moores Cancer Ccancer patients, but our research attempted to go further by demonstrating the impact of race - based inequalities in cancer treatment on survival rates of black colorectal cancer patients,» said James D. Murphy, MD, MS, assistant professor and chief of the Radiation Oncology Gastrointestinal Tumor Service at UC San Diego Moores Cancer Ccancer treatment on survival rates of black colorectal cancer patients,» said James D. Murphy, MD, MS, assistant professor and chief of the Radiation Oncology Gastrointestinal Tumor Service at UC San Diego Moores Cancer Ccancer patients,» said James D. Murphy, MD, MS, assistant professor and chief of the Radiation Oncology Gastrointestinal Tumor Service at UC San Diego Moores Cancer CCancer Center.

This study was supported by Norma C. and Albert I. Geller via the Gynecological Cancer Translation Research Program at the Case Comprehensive Cancer Center, and grants from The Mary Kay Foundation (to A.D. and R.X.), the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator award number DP2HD084068 (to R.X.), The National Cancer Institute award number R011CA197780 - 01A1 (to A.D.), and The Young Scientist Foundation (A.D.).

Study authors are Anjie Zhen, Mayra Carrillo, Cindy Youn, Brianna Lam, Nelson Chang, Heather Martin, Jonathan Rick, Jennifer Kim, Nick Neel, Valerie Rezek, Masakazu Kamata, Irvin Chen, Jerome Zack, and Scott Kitchen of UCLA; Christopher W. Peterson and Hans - Peter Kiem of the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle; and Sowmya Somashekar Reddy of the Hutchinson Center.

«We can use expansion pathology to push conventional light microscopes beyond their current limits, which could have important applications in diagnostic pathology,» said the study's co-lead author, Octavian Bucur, MD, PhD, of the Department of Pathology and Cancer Research Institute at BIDMC, who is also a Ludwig Cancer Center Research Investigator.

«This research is an important advance in the potential expansion of fertility preservation options for young patients who may not be able to undergo hormone stimulation to induce ovulation before beginning chemotherapy,» says study author Jacqueline S. Jeruss, M.D., Ph.D., associate professor of surgery and director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center.

In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutacancer patients with B - raf mutations.

Screening for colorectal cancer based on age alone may contribute to both underuse and overuse of the tests among older patients, according to a study by investigators at the University of Michigan and the Veterans Affairs Center for Clinical Management Research.

The results, which are presented today at the 30th Annual Meeting of ESHRE in Munich by Dr Allan Jensen of the Danish Cancer Society Research Center at the University of Copenhagen, were derived from a register study of all children born in Denmark between 1969 and 2006.

«We challenged a current dogma in the field that emphasized PLK1's role in mitosis (cell division) as a primary mechanism for cancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Medcancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of MedCancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of MedCancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Medicine.

The results of the study were published this week in the journal Nature Medicine from researchers at Penn's Abramson Cancer Center, including senior author Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the ACC, the University of Maryland School of Medicine, and Adaptimmune Therapeutics plc (Adaptimmune).

A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug covCancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug covCancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug covcancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug coverage.

We found that performing MRI before biopsy and using that information to alter biopsy pathways would be a strategy that would add health benefits to the patient population in a cost effective manner,» said Vikas Gulani, MD, PhD, study advisor and associate professor of radiology, urology, and biomedical engineering at Case Western Reserve University School of Medicine, and member of both the Case Comprehensive Cancer Center and Case Center for Imaging Research.

The research was supported by the Howard Hughes Medical Institute, National Natural Science Foundation of China, National Institute of Diabetes and Digestive and Kidney Diseases (Grant DK106309), National Cancer Institute (Grant CA168654), and Center for Molecular Studies in Digestive and Liver Diseases (Grant DK050306).

«Our ability to see this fundamental process in cancer formation was possible only because of access to revolutionary imaging technology,» said the study's senior author, Tom Misteli, Ph.D., Laboratory of Receptor Biology and Gene Expression, Center for Cancer Researchcancer formation was possible only because of access to revolutionary imaging technology,» said the study's senior author, Tom Misteli, Ph.D., Laboratory of Receptor Biology and Gene Expression, Center for Cancer ResearchCancer Research, NCI.

Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Instcancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer InstCancer Center The research is published online in the Journal of the National Cancer InstCancer Institute.

The study, published in PLOS Medicine, was led by Wei Zheng, M.D., Ph.D., MPH, professor of Medicine and director of the Vanderbilt Epidemiology Center, and John Potter, M.D., Ph.D., a member and scientific advisor of the Fred Hutchinson Cancer Research Center, Seattle, Washington.

Other UT Southwestern researchers involved in the study were Dr. Ramzi Abdulrahman, Associate Professor of Radiation Oncology; Dr. Arthur Sagalowsky, Professor of Urology and Surgery, co-leader of the Kidney Cancer Program, who holds The Dr. Paul Peters Chair in Urology in Memory of Rumsey and Louis Strickland; Dr. Ivan Pedrosa, Associate Professor of Radiology and the Advanced Imaging Research Center, co-leader of the Kidney Cancer Program, who holds the Jack Reynolds, M.D., Chair in Radiology; Dr. Hak Choy, Chair and Professor of Radiation Oncology who holds The Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research; and Dr. James Brugarolas, Associate Professor of Internal Medicine and Developmental Biology, leader of the Kidney Cancer Program, and Virginia Murchison Linthicum Endowed Scholar; and other researchers including Stephen Chun, Dr. Nathan Cannon, and Dr. Nathan Kim.

«Research in the last couple of decades has shown that microbes can exploit [cell death] pathways to cause disease,» says study coauthor Tobias Hohl, an infectious disease researcher at Memorial Sloan Kettering Cancer Center in New York City.

«We have revealed novel components and connections in the regulatory network underlying how these T cells mount an immune response,» said study co-leader Kai Tan, PhD, of the Center for Childhood Cancer Research and the Departments of Pediatrics and Biomedical and Health Informatics at CHOP.